Cantor Fitzgerald Forecasts Legend Biotech FY2025 Earnings

Legend Biotech Co. (NASDAQ:LEGN) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Legend Biotech in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings per share of ($0.72) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $83.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.24) per share.

Several other research analysts have also commented on LEGN. Redburn Atlantic assumed coverage on shares of Legend Biotech in a research note on Tuesday, October 8th. They set a “buy” rating and a $86.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a research report on Monday, December 30th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a research note on Tuesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Legend Biotech in a research note on Monday, December 9th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $80.62.

Legend Biotech Stock Performance

Shares of Legend Biotech stock opened at $37.69 on Wednesday. The company has a market capitalization of $6.88 billion, a PE ratio of -39.67 and a beta of 0.16. The company has a 50-day simple moving average of $36.44 and a two-hundred day simple moving average of $45.77. Legend Biotech has a one year low of $30.17 and a one year high of $70.13. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.22. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm had revenue of $160.20 million during the quarter, compared to analyst estimates of $143.91 million. During the same period in the previous year, the company posted ($0.17) EPS. The business’s revenue for the quarter was up 66.9% compared to the same quarter last year.

Institutional Investors Weigh In On Legend Biotech

Several large investors have recently bought and sold shares of LEGN. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Legend Biotech by 31.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,540 shares of the company’s stock worth $290,000 after acquiring an additional 1,571 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Legend Biotech by 9.9% in the 2nd quarter. Hsbc Holdings PLC now owns 232,560 shares of the company’s stock valued at $10,296,000 after purchasing an additional 20,910 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in Legend Biotech by 11.8% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 12,300 shares of the company’s stock worth $545,000 after purchasing an additional 1,300 shares during the last quarter. Sei Investments Co. boosted its stake in Legend Biotech by 1.5% during the 2nd quarter. Sei Investments Co. now owns 46,492 shares of the company’s stock worth $2,059,000 after purchasing an additional 702 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its holdings in shares of Legend Biotech by 1.6% during the second quarter. Public Sector Pension Investment Board now owns 24,689 shares of the company’s stock worth $1,093,000 after buying an additional 400 shares in the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).